Your request has been received.
We will send you more information as it becomes available.
Effective January 1, 2025: ASP+6% reimbursement for EXPAREL when billing with code J0666 across all outpatient surgical settings.
This case study represents an individual clinician experience with and methodology for using EXPAREL.
Pacira BioSciences, Inc., recognizes that there are other methodologies for administering local anesthetics, as well as individual patient considerations, when selecting the dose for a specific procedure.
Please see Important Safety Information below and refer to the Full Prescribing Information.
Disclosure: Dr Amin is a paid consultant for Pacira BioSciences, Inc.
The recommended dose of EXPAREL for infiltration in adults is based on the size of the surgical site, the volume required to cover the area, and individual patient factors that may impact the safety of an amide local anesthetic. The maximum dose of EXPAREL should not exceed 266 mg. The recommended dose of EXPAREL for patients aged 6 to <17 years old is 4 mg/kg, up to a maximum of 266 mg. The recommended dose of EXPAREL in adults for interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and adductor canal is 133 mg. The recommended dose of EXPAREL in adults for adductor canal block is 133 mg (10 mL) admixed with 50 mg (10 mL) of 0.5% bupivacaine HCl, for a total volume of 20 mL.
EXPAREL can be administered unexpanded (20 mL) or expanded to increase volume up to a total of 300 mL (final concentration of 0.89 mg/mL [ie, 1:14 dilution by volume]) with normal (0.9%) saline or lactated Ringer’s solution.
Bupivacaine HCl (which is approved for use in patients aged 12 and older) may be administered immediately before EXPAREL or admixed in the same syringe, as long as the ratio of the milligram dose of bupivacaine HCl to EXPAREL does not exceed 1:2. Admixing may impact the pharmacokinetic and/or physicochemical properties of EXPAREL, and this effect is concentration dependent. The toxic effects of these drugs are additive and their administration should be used with caution, including monitoring for neurological and cardiovascular effects related to local anesthetic systemic toxicity. Other than with bupivacaine, EXPAREL should not be admixed with other drugs prior to administration.
ASSESSED THE SIZE OF THE SURGICAL SITE AND DEPTH OF TISSUE, THEN PREPARED INJECTION MATERIALS ACCORDINGLY
In this procedure, Dr Amin determined that a total volume of 120 mL would be needed to cover the surgical sites. He expanded 20 mL of EXPAREL® (bupivacaine liposome injectable suspension) with 80 mL of normal saline and admixed the solution with 20 mL of 0.5% bupivacaine HCI. Dr Amin added bupivacaine HCl to provide short-term local analgesia in the postanesthesia care unit that overlapped with the long-term local analgesia provided by EXPAREL.
DIVIDED INJECTATE INTO SYRINGES WITH NEEDLE GAUGES APPROPRIATE FOR INFILTRATION (20- TO 25-GAUGE) AND PLANNED WHICH AREAS TO INFILTRATE WITH EACH INJECTION
For this procedure, Dr Amin divided the injectate into six 20-mL syringes using a 22-gauge needle and infiltrated as follows:
Infiltrated 20 mL of expanded EXPAREL® (bupivacaine liposome injectable suspension) into the soft tissue surrounding the nail entry site and the periosteum. Needle was advanced deep into the tissue until tip of great trochanter region was felt, and approximately 1 to 3 mL of expanded EXPAREL was injected as the needle was pulled back. This was repeated several times until the entire syringe was injected.
FIGURE 1. Soft tissue and periosteum around nail entry site
Infiltrated 10 mL superior and 10 mL inferior to the nail entry site, directly into the periosteum. Any remaining injectate was infiltrated into the surrounding superficial soft tissue. 1- to 2-mL injections were spread approximately 1 cm apart to ensure infiltration of the entire soft tissue envelope.
FIGURE 2. Superior and inferior to nail entry site, into periosteum
Infiltrated 10 mL anterior and 10 mL posterior to the lateral cortex of the hip screw site, directly into the periosteum. Injected in approximately 1- to 2-mL increments to ensure analgesic coverage of the proximal screw site and surrounding soft tissue.
FIGURE 3. Anterior and posterior to hip screw site, into periosteum
Infiltrated 10 mL into the superficial tissue planes of the hip s crew site in 1- to 2-mL increments spread 1 cm apart.
Under direct fluoroscopic imaging, infiltrated remaining 10 mL into the fracture hematoma site.
FIGURE 4. Superior to hip screw site, into periosteum
Under direct fluoroscopic imaging, infiltrated 20 mL into the fracture hematoma site.
FIGURE 5. Fracture hematoma site
Avoid injecting posteriorly due to the proximity to the sciatic nerve and other neurovascular structures.
Infiltrated 10 mL into the periosteum and soft tissue of each distal interlock site (total of 20 mL).
FIGURE 6. Soft tissue and periosteum of distal interlock sites
If there are fewer than 2 distal locking screws, use 10 mL at the distal interlock site and infiltrate remainder of syringe #6 into either the hip screw site or the nail entry site.
Dr Amin infiltrated EXPAREL® (bupivacaine liposome injectable suspension) into all tissue layers using a moving needle technique. With a moving needle technique, the injections were spread in a fan-like pattern and occurred as the needle was withdrawn to maximize the coverage area. This technique was systematically and meticulously repeated at each injection site, with overlapping diffusion of EXPAREL to ensure there were no gaps in analgesic coverage.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.